Michael Thomas Henderson, Director at Spyre Therapeutics, Inc. (SYRE), sold 80,000 shares at $72.57 ($6.0M) on 2026-05-08, disclosed to the SEC on 2026-05-08.
Scheduled sale ($6.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $72.57 | 2,404 | $174K | 2.9% |
| 2 | $73.72 | 33,513 | $2.5M | 41.5% |
| 3 | $74.76 | 24,814 | $1.9M | 31.2% |
| 4 | $75.35 | 19,269 | $1.5M | 24.4% |
| Total | $74.40 avg | 80,000 | $6.0M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |